| Mr James Marsh Cunningham, MA, LPA | |
|
350 Pee Dee Ave, Albemarle, NC 28001-4932 | |
| (704) 986-1573 | |
| Not Available |
| Full Name | Mr James Marsh Cunningham |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 350 Pee Dee Ave, Albemarle, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679861934 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 1025 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr James Marsh Cunningham, MA, LPA 3324 Johnny Cake Ln, Charlotte, NC 28226-6630 Ph: (704) 643-9222 | Mr James Marsh Cunningham, MA, LPA 350 Pee Dee Ave, Albemarle, NC 28001-4932 Ph: (704) 986-1573 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
MarketResearch.com has announced the addition of Global Markets Direct's new report "Global Patient Monitoring Investment Opportunities, Analysis and Forecasts to 2015," to their collection of Patient Monitoring market reports.
Adheris, Inc., an inVentiv Health company, filed suit today against the U.S. Department of Health and Human Services, asking a federal court to enjoin the government from implementing a new regulation that imposes unconstitutional restrictions on the speech of a company whose business is encouraging patients to properly take their medicine.
Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).
Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.
› Verified 2 days ago
Amanda Matthews, MA,LPA,HSP-PA,CSOTS Psychologist Medicare: Not Enrolled in Medicare Practice Location: 350 Pee Dee Ave, Albemarle, NC 28001 Phone: 704-986-1500 | |
Janet Stephens Banks, M.A. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 213 N 2nd St, Albemarle, NC 28001 Phone: 704-982-9600 Fax: 704-982-8155 | |
Jacita Booker Petway, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1000 N 1st St Ste 1, Albemarle, NC 28001 Phone: 704-938-2117 Fax: 704-938-2636 | |
Mrs. Santina A Pfleeger, MA-LPA, HSP-PA Psychologist Medicare: Not Enrolled in Medicare Practice Location: 130 N 1st St, Albemarle, NC 28001 Phone: 704-983-1134 Fax: 704-982-2552 | |
Virginia Elaine Fee, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 1040 E Main St, Albemarle, NC 28001 Phone: 704-984-4910 | |
Connie Smith Philbeck, L.P.A. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 N 1st St, Albemarle, NC 28001 Phone: 704-983-2117 |